Our continuously expanding portfolio features 20+ high-quality monoclonal antibodies (MAbs), each rigorously validated for in vivo applications. These scientifically characterised reagents are immediately available in milligram to multi-gram quantities, supported by UK-based rapid delivery for reliable supply chain continuity.
Key offerings include:
· Blocking MAbs targeting epitopes with defined specificity.
· Functional MAbs and biosimilar controls for mechanistic pharmacology studies
· Species-specific anti-mouse reagents optimised to eliminate cross-reactivity confounders.
All products undergo three-tier quality assurance, ensuring reproducibility in preclinical models. Our iterative development pipeline ensures sustained availability of novel reagents addressing emerging therapeutic targets.
131 citations